Praxis Precision Medicine saw a 251% increase in shares after announcing successful phase 3 trial results with their lead candidate for essential tremor patients. With three late-clinical-stage assets in their pipeline, Praxis is capturing investor attention in the biotechnology sector. The company’s ulixacaltamide showed promising results in reducing tremors, indicating potential for billions in annual sales. However, Praxis remains a pre-commercial company, presenting risks for investors. Their pipeline also includes vormatrigine for epilepsy and relutrigine for developmental epilepsies, offering further growth potential. Consider Praxis stock cautiously due to the inherent risks associated with clinical-stage biotech companies.

Read more at Nasdaq: Meet the Biotech Stock That Just Jumped 251% Higher